Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDQuarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
---|---|---|---|---|
Q1 2024 | 1 | -$0.14 | -$0.13 | -$0.14 |
Q2 2024 | 1 | $0.01 | $0.01 | $0.01 |
Q3 2024 | 1 | $0.01 | $0.02 | $0.02 |
Q4 2024 | 4 | -$0.01 | $0.04 | $0.02 |
Q1 2025 | 2 | $0.10 | $0.11 | $0.11 |
Q2 2025 | 1 | $0.11 | $0.13 | $0.12 |
Q3 2025 | 1 | $0.12 | $0.13 | $0.13 |
Q4 2025 | 1 | $0.14 | $0.16 | $0.15 |
Aurinia Pharmaceuticals Inc. last posted its earnings results on Thursday, November 7th, 2024. The company reported $0.1 earnings per share for the quarter, topping analysts' consensus estimates of $0.015 by $0.085. The company had revenue of 67.77 M for the quarter and had revenue of 175.51 M for the year. Aurinia Pharmaceuticals Inc. has generated $-1 earnings per share over the last year ($-0.54 diluted earnings per share) and currently has a price-to-earnings ratio of -56.96. Aurinia Pharmaceuticals Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, February 13th, 2025 based on prior year's report dates.
Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
---|---|---|---|---|---|---|
11/07/2024 | Q3 2024 | $0.02 | $0.10 | 0.09 | $57.48 M | $67.77 M |
08/01/2024 | Q2 2024 | $0.02 | $0.01 | -0.01 | $54.25 M | $57.19 M |
05/02/2024 | Q1 2024 | -$0.17 | -$0.07 | 0.1 | $50.30 M | |
04/29/2024 | Q4 2023 | -$0.19 | $45.10 M | |||
11/02/2023 | Q3 2023 | -$0.17 | -$0.09 | 0.08 | $38.44 M | $54.52 M |
08/03/2023 | Q2 2023 | -$0.20 | -$0.08 | 0.12 | $37.90 M | $41.49 M |
05/04/2023 | Q1 2023 | -$0.24 | -$0.18 | 0.06 | $34.41 M | |
02/28/2023 | Q4 2022 | -$0.26 | -$0.18 | 0.08 | $28.44 M | |
11/03/2022 | Q3 2022 | -$0.18 | -$0.06 | 0.12 | $36.19 M | $55.78 M |
08/04/2022 | Q2 2022 | -$0.22 | -$0.25 | -0.03 | $27.04 M | $28.19 M |
05/10/2022 | Q1 2022 | -$0.26 | -$0.27 | -0.01 | $21.63 M | |
02/28/2022 | Q4 2021 | -$0.26 | -$0.25 | 0.01 | $23.40 M | |
11/03/2021 | Q3 2021 | -$0.31 | -$0.39 | -0.08 | $13.87 M | $14.67 M |
08/05/2021 | Q2 2021 | -$0.35 | -$0.37 | -0.02 | $4.96 M | $6.62 M |
05/06/2021 | Q1 2021 | -$0.35 | -$0.40 | -0.05 | $914,000 | |
02/24/2021 | Q4 2020 | -$0.31 | -$0.06 | 0.25 | $50.03 M | |
09/29/2020 | Q3 2020 | -$0.28 | $43,429 | $29,000 | ||
07/21/2020 | Q2 2020 | -$0.26 | $27,556 | $29,000 | ||
04/20/2020 | Q1 2020 | -$0.20 | -$0.15 | 0.05 | $30,000 | |
02/25/2020 | Q4 2019 | -$0.78 | $29,000 |
Aurinia Pharmaceuticals Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, February 13th, 2025 based off last year's report dates.
In the previous quarter, Aurinia Pharmaceuticals Inc. (:AUPH) reported $0.1 earnings per share (EPS) to beat the analysts' consensus estimate of $0.015 by $0.085.
The conference call for Aurinia Pharmaceuticals Inc.'s latest earnings report can be listened to online.
The conference call transcript for Aurinia Pharmaceuticals Inc.'s latest earnings report can be read online.
Aurinia Pharmaceuticals Inc. (:AUPH) has a recorded annual revenue of $175.51 M.
Aurinia Pharmaceuticals Inc. (:AUPH) has a recorded net income of $175.51 M. Aurinia Pharmaceuticals Inc. has generated $-0.54 earnings per share over the last four quarters.
Aurinia Pharmaceuticals Inc. (:AUPH) has a price-to-earnings ratio of -56.96 and price/earnings-to-growth ratio is -1.05.
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTED